Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MET-TFG

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MET-TFG
	FusionPDB ID: 53038
	FusionGDB2.0 ID: 53038
		Hgene	Tgene
	Gene symbol	MET	TFG
	Gene ID	8731	10342
	Gene name	RNA guanine-7 methyltransferase	trafficking from ER to golgi regulator
	Synonyms	CMT1\|CMT1c\|MET\|Met\|RG7MT1\|cm1p\|hCMT1\|hMet	HMSNP\|SPG57\|TF6\|TRKT3
	Cytomap	18p11.21	3q12.2
	Type of gene	protein-coding	protein-coding
	Description	mRNA cap guanine-N7 methyltransferaseRNA (guanine-7-) methyltransferasehcm1pmRNA (guanine-7-)methyltransferasemRNA (guanine-N(7)-)-methyltransferasemRNA cap methyltransferase	protein TFGTRK-fusedTRK-fused gene proteinTRKT3 oncogene
	Modification date	20200329	20200313
	UniProtAcc	Q9H1A3 Main function of 5'-partner protein:	Q92734 Main function of 5'-partner protein: FUNCTION: Plays a role in the normal dynamic function of the endoplasmic reticulum (ER) and its associated microtubules (PubMed:23479643, PubMed:27813252). Required for secretory cargo traffic from the endoplasmic reticulum to the Golgi apparatus (PubMed:21478858). {ECO:0000269\|PubMed:21478858, ECO:0000269\|PubMed:23479643, ECO:0000269\|PubMed:27813252}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000318493, ENST00000397752, ENST00000436117, ENST00000495962, ENST00000539704,	ENST00000481203, ENST00000240851, ENST00000418917, ENST00000476228, ENST00000490574,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	11 X 10 X 9=990	8 X 7 X 5=280
	# samples	16	9
	** MAII score	log2(16/990*10)=-2.62935662007961 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(9/280*10)=-1.63742992061529 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: MET [Title/Abstract] AND TFG [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MET [Title/Abstract] AND TFG [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MET(116412043)-TFG(100455420), # samples:3 TFG(100451516)-MET(116414935), # samples:3
Anticipated loss of major functional domain due to fusion event.	MET-TFG seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MET-TFG seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MET-TFG seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MET-TFG seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TFG-MET seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TFG-MET seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MET	GO:0006370	7-methylguanosine mRNA capping	27422871

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:116412043/chr3:100455420)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MET (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across TFG (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000397752	MET	chr7	116412043	+	ENST00000418917	TFG	chr3	100455420	+	4250	3228	200	3838	1212
ENST00000397752	MET	chr7	116412043	+	ENST00000490574	TFG	chr3	100455420	+	4247	3228	200	3850	1216
ENST00000397752	MET	chr7	116412043	+	ENST00000240851	TFG	chr3	100455420	+	4286	3228	200	3850	1216
ENST00000397752	MET	chr7	116412043	+	ENST00000476228	TFG	chr3	100455420	+	4272	3228	200	3838	1212
ENST00000318493	MET	chr7	116412043	+	ENST00000418917	TFG	chr3	100455420	+	4291	3269	187	3879	1230
ENST00000318493	MET	chr7	116412043	+	ENST00000490574	TFG	chr3	100455420	+	4288	3269	187	3891	1234
ENST00000318493	MET	chr7	116412043	+	ENST00000240851	TFG	chr3	100455420	+	4327	3269	187	3891	1234
ENST00000318493	MET	chr7	116412043	+	ENST00000476228	TFG	chr3	100455420	+	4313	3269	187	3879	1230
ENST00000397752	MET	chr7	116412043	+	ENST00000418917	TFG	chr3	100455419	+	4250	3228	200	3838	1212
ENST00000397752	MET	chr7	116412043	+	ENST00000490574	TFG	chr3	100455419	+	4247	3228	200	3850	1216
ENST00000397752	MET	chr7	116412043	+	ENST00000240851	TFG	chr3	100455419	+	4286	3228	200	3850	1216
ENST00000397752	MET	chr7	116412043	+	ENST00000476228	TFG	chr3	100455419	+	4272	3228	200	3838	1212
ENST00000318493	MET	chr7	116412043	+	ENST00000418917	TFG	chr3	100455419	+	4291	3269	187	3879	1230
ENST00000318493	MET	chr7	116412043	+	ENST00000490574	TFG	chr3	100455419	+	4288	3269	187	3891	1234
ENST00000318493	MET	chr7	116412043	+	ENST00000240851	TFG	chr3	100455419	+	4327	3269	187	3891	1234
ENST00000318493	MET	chr7	116412043	+	ENST00000476228	TFG	chr3	100455419	+	4313	3269	187	3879	1230

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000397752	ENST00000418917	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000253288	0.99974674
ENST00000397752	ENST00000490574	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000225893	0.99977416
ENST00000397752	ENST00000240851	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.00021547	0.9997845
ENST00000397752	ENST00000476228	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000246873	0.9997532
ENST00000318493	ENST00000418917	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000401519	0.99959844
ENST00000318493	ENST00000490574	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000256947	0.99974304
ENST00000318493	ENST00000240851	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000244547	0.99975544
ENST00000318493	ENST00000476228	MET	chr7	116412043	+	TFG	chr3	100455420	+	0.000392739	0.99960726
ENST00000397752	ENST00000418917	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000253288	0.99974674
ENST00000397752	ENST00000490574	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000225893	0.99977416
ENST00000397752	ENST00000240851	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.00021547	0.9997845
ENST00000397752	ENST00000476228	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000246873	0.9997532
ENST00000318493	ENST00000418917	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000401519	0.99959844
ENST00000318493	ENST00000490574	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000256947	0.99974304
ENST00000318493	ENST00000240851	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000244547	0.99975544
ENST00000318493	ENST00000476228	MET	chr7	116412043	+	TFG	chr3	100455419	+	0.000392739	0.99960726

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MET-TFG

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MET	chr7	116412043	TFG	chr3	100455419	3228	1009	SNESVDYRATFPEGPPSAPAEDRSGT
MET	chr7	116412043	TFG	chr3	100455419	3269	1027	SNESVDYRATFPEGPPSAPAEDRSGT
MET	chr7	116412043	TFG	chr3	100455420	3228	1009	SNESVDYRATFPEGPPSAPAEDRSGT
MET	chr7	116412043	TFG	chr3	100455420	3269	1027	SNESVDYRATFPEGPPSAPAEDRSGT

Top

Potential FusionNeoAntigen Information of MET-TFG in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MET-TFG_116412043_100455419.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:01	FPEGPPSA	0.9972	0.673	10	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:01	FPEGPPSAP	0.9772	0.7085	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B35:02	FPEGPPSAP	0.8176	0.9853	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B35:04	FPEGPPSAP	0.8176	0.9853	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:01	FPEGPPSAPA	0.9947	0.9162	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B55:01	FPEGPPSAPA	0.9876	0.7728	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-A30:08	ATFPEGPPSA	0.8344	0.9414	8	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-A02:21	ATFPEGPPSA	0.8145	0.7515	8	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B54:01	FPEGPPSA	0.9987	0.8868	10	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B78:01	FPEGPPSA	0.9967	0.9658	10	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B54:01	FPEGPPSAP	0.9958	0.8498	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B73:01	YRATFPEGP	0.9719	0.8049	6	15
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:04	FPEGPPSAP	0.9133	0.6862	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B35:12	FPEGPPSAP	0.8176	0.9853	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-C04:14	TFPEGPPSA	0.5828	0.9855	9	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B78:01	FPEGPPSAP	0.5559	0.9705	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B54:01	FPEGPPSAPA	0.9987	0.9707	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:04	FPEGPPSAPA	0.9895	0.8901	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B78:01	FPEGPPSAPA	0.829	0.9829	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B55:02	FPEGPPSA	0.9967	0.736	10	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B78:02	FPEGPPSA	0.9967	0.9893	10	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:05	FPEGPPSA	0.9966	0.9131	10	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B55:02	FPEGPPSAP	0.9572	0.7277	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:02	FPEGPPSAP	0.9133	0.6862	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B35:09	FPEGPPSAP	0.8176	0.9853	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:05	FPEGPPSAP	0.73	0.9274	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B67:01	FPEGPPSAP	0.5885	0.9871	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B78:02	FPEGPPSAP	0.4601	0.9786	10	19
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-C14:03	TFPEGPPSA	0.2736	0.9912	9	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-C14:02	TFPEGPPSA	0.2736	0.9912	9	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B55:02	FPEGPPSAPA	0.9935	0.9313	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:02	FPEGPPSAPA	0.9895	0.8901	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B67:01	FPEGPPSAPA	0.9094	0.9922	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B56:05	FPEGPPSAPA	0.9068	0.9521	10	20
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-A02:06	ATFPEGPPSA	0.8145	0.7515	8	18
MET-TFG	chr7	116412043	chr3	100455419	3269	HLA-B78:02	FPEGPPSAPA	0.7041	0.9865	10	20

Top

Potential FusionNeoAntigen Information of MET-TFG in HLA II

MET-TFG_116412043_100455419.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MET-TFG	chr7	116412043	chr3	100455419	3269	DRB1-0806	NESVDYRATFPEGPP	1	16
MET-TFG	chr7	116412043	chr3	100455419	3269	DRB1-1457	NESVDYRATFPEGPP	1	16

Top

Fusion breakpoint peptide structures of MET-TFG

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10782	YRATFPEGPPSAPA	MET	TFG	chr7	116412043	chr3	100455419	3269

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MET-TFG

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	10782	YRATFPEGPPSAPA	-7.15543	-7.26883
HLA-B14:02	3BVN	10782	YRATFPEGPPSAPA	-4.77435	-5.80965
HLA-B52:01	3W39	10782	YRATFPEGPPSAPA	-6.80875	-6.92215
HLA-B52:01	3W39	10782	YRATFPEGPPSAPA	-4.20386	-5.23916
HLA-A11:01	4UQ2	10782	YRATFPEGPPSAPA	-7.5194	-8.5547
HLA-A11:01	4UQ2	10782	YRATFPEGPPSAPA	-6.9601	-7.0735
HLA-A24:02	5HGA	10782	YRATFPEGPPSAPA	-7.52403	-7.63743
HLA-A24:02	5HGA	10782	YRATFPEGPPSAPA	-5.82433	-6.85963
HLA-B27:05	6PYJ	10782	YRATFPEGPPSAPA	-3.28285	-4.31815
HLA-B44:05	3DX8	10782	YRATFPEGPPSAPA	-5.91172	-6.94702
HLA-B44:05	3DX8	10782	YRATFPEGPPSAPA	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of MET-TFG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MET-TFG	chr7	116412043	chr3	100455419	10	18	FPEGPPSA	TTCCAGAAGGGCCACCCAGTGCTC
MET-TFG	chr7	116412043	chr3	100455419	10	19	FPEGPPSAP	TTCCAGAAGGGCCACCCAGTGCTCCTG
MET-TFG	chr7	116412043	chr3	100455419	10	20	FPEGPPSAPA	TTCCAGAAGGGCCACCCAGTGCTCCTGCAG
MET-TFG	chr7	116412043	chr3	100455419	6	15	YRATFPEGP	ACCGAGCTACTTTTCCAGAAGGGCCAC
MET-TFG	chr7	116412043	chr3	100455419	8	18	ATFPEGPPSA	CTACTTTTCCAGAAGGGCCACCCAGTGCTC
MET-TFG	chr7	116412043	chr3	100455419	9	18	TFPEGPPSA	CTTTTCCAGAAGGGCCACCCAGTGCTC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
MET-TFG	chr7	116412043	chr3	100455419	1	16	NESVDYRATFPEGPP	ATGAATCTGTAGACTACCGAGCTACTTTTCCAGAAGGGCCACCCA

Top

Information of the samples that have these potential fusion neoantigens of MET-TFG

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
THCA	MET-TFG	chr7	116412043	ENST00000318493	chr3	100455419	ENST00000240851	TCGA-FK-A3S3

Top

Potential target of CAR-T therapy development for MET-TFG

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MET

chr7:116412043

chr3:100455419

ENST00000318493

933_955

1027

1409.0

Transmembrane

Helical

Hgene

MET

chr7:116412043

chr3:100455419

ENST00000397752

933_955

1009

1391.0

Transmembrane

Helical

Hgene

MET

chr7:116412043

chr3:100455420

ENST00000318493

933_955

1027

1409.0

Transmembrane

Helical

Hgene

MET

chr7:116412043

chr3:100455420

ENST00000397752

933_955

1009

1391.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MET-TFG

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MET-TFG

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Tgene	TFG	C3714897	SPASTIC PARAPLEGIA 57, AUTOSOMAL RECESSIVE	5	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene	TFG	C1858338	Neuropathy, hereditary motor and sensory, Okinawa type	4	CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
Tgene	TFG	C0238463	Papillary thyroid carcinoma	2	ORPHANET
Tgene	TFG	C0442874	Neuropathy	1	GENOMICS_ENGLAND
Tgene	TFG	C1275278	Extraskeletal Myxoid Chondrosarcoma	1	GENOMICS_ENGLAND;ORPHANET
Tgene	TFG	C3714756	Intellectual Disability	1	GENOMICS_ENGLAND

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)